Cargando…
Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells
microRNA-22 (miR-22) is a key regulator of lipid and energy homeostasis and represents a promising therapeutic target for NAFLD and obesity. We have previously identified a locked nucleic acid (LNA)-modified antisense oligonucleotide compound complementary to miR-22, designated as RES-010 that media...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076763/ https://www.ncbi.nlm.nih.gov/pubmed/37033600 http://dx.doi.org/10.3389/fphar.2023.1125654 |
_version_ | 1785020205686063104 |
---|---|
author | Panella, Riccardo Zanderigo, Floriana Morandini, Francesca Federico, Denise Vicentini, Elena Andreetta, Filippo Toniolo, Alessandro Kauppinen, Sakari |
author_facet | Panella, Riccardo Zanderigo, Floriana Morandini, Francesca Federico, Denise Vicentini, Elena Andreetta, Filippo Toniolo, Alessandro Kauppinen, Sakari |
author_sort | Panella, Riccardo |
collection | PubMed |
description | microRNA-22 (miR-22) is a key regulator of lipid and energy homeostasis and represents a promising therapeutic target for NAFLD and obesity. We have previously identified a locked nucleic acid (LNA)-modified antisense oligonucleotide compound complementary to miR-22, designated as RES-010 that mediated robust inhibition of miR-22 function in cultured cells and in vivo. In this study we investigated the immune potential of RES-010 in human peripheral blood mononuclear cells (PBMCs). We treated fresh human peripheral blood mononuclear cells isolated from six healthy volunteers with different concentrations of the RES-010 compound and assessed its proinflammatory effects by quantifying IL-1β, IL-6, IFN-γ, TNF-α, IFN-α2a, IFN-β, IL-10, and IL-17A in the supernatants collected 24 h of treatment with RES-010. The T-cell activation markers, CD69, HLA-DR, and CD25 were evaluated by flow cytometry after 24 and 144 h of treatment, respectively, whereas cell viability was assessed after 24 h of treatment with RES-010. Our results show that RES-010 compound does not induce any significant immunostimulatory responses in human PBMCs in vitro compared to controls, implying that the proinflammatory potential of RES-010 is low. |
format | Online Article Text |
id | pubmed-10076763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100767632023-04-07 Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells Panella, Riccardo Zanderigo, Floriana Morandini, Francesca Federico, Denise Vicentini, Elena Andreetta, Filippo Toniolo, Alessandro Kauppinen, Sakari Front Pharmacol Pharmacology microRNA-22 (miR-22) is a key regulator of lipid and energy homeostasis and represents a promising therapeutic target for NAFLD and obesity. We have previously identified a locked nucleic acid (LNA)-modified antisense oligonucleotide compound complementary to miR-22, designated as RES-010 that mediated robust inhibition of miR-22 function in cultured cells and in vivo. In this study we investigated the immune potential of RES-010 in human peripheral blood mononuclear cells (PBMCs). We treated fresh human peripheral blood mononuclear cells isolated from six healthy volunteers with different concentrations of the RES-010 compound and assessed its proinflammatory effects by quantifying IL-1β, IL-6, IFN-γ, TNF-α, IFN-α2a, IFN-β, IL-10, and IL-17A in the supernatants collected 24 h of treatment with RES-010. The T-cell activation markers, CD69, HLA-DR, and CD25 were evaluated by flow cytometry after 24 and 144 h of treatment, respectively, whereas cell viability was assessed after 24 h of treatment with RES-010. Our results show that RES-010 compound does not induce any significant immunostimulatory responses in human PBMCs in vitro compared to controls, implying that the proinflammatory potential of RES-010 is low. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076763/ /pubmed/37033600 http://dx.doi.org/10.3389/fphar.2023.1125654 Text en Copyright © 2023 Panella, Zanderigo, Morandini, Federico, Vicentini, Andreetta, Toniolo and Kauppinen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Panella, Riccardo Zanderigo, Floriana Morandini, Francesca Federico, Denise Vicentini, Elena Andreetta, Filippo Toniolo, Alessandro Kauppinen, Sakari Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells |
title | Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells |
title_full | Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells |
title_fullStr | Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells |
title_full_unstemmed | Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells |
title_short | Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells |
title_sort | assessment of immunostimulatory responses to the antimir-22 oligonucleotide compound res-010 in human peripheral blood mononuclear cells |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076763/ https://www.ncbi.nlm.nih.gov/pubmed/37033600 http://dx.doi.org/10.3389/fphar.2023.1125654 |
work_keys_str_mv | AT panellariccardo assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells AT zanderigofloriana assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells AT morandinifrancesca assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells AT federicodenise assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells AT vicentinielena assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells AT andreettafilippo assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells AT tonioloalessandro assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells AT kauppinensakari assessmentofimmunostimulatoryresponsestotheantimir22oligonucleotidecompoundres010inhumanperipheralbloodmononuclearcells |